Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2002 Jun;50(6):840-4.
doi: 10.1136/gut.50.6.840.

Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial

J H Scholefield  1 , S Moss, F Sufi, C M Mangham, J D Hardcastle
Affiliations
Clinical Trial

Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial

J H Scholefield et al. Gut. 2002 Jun.

Abstract

Background: Three large randomised trials have shown that screening for colorectal cancer using faecal occult blood (FOB) tests can reduce the mortality from this disease. Two national pilot studies have recently been launched in the UK to investigate the feasibility of population screening for colorectal cancer in the National Health Service. The largest of the randomised trials was conducted in Nottingham and randomised 152 850 individuals between the ages of 45 and 74 years to receive biennial Haemoccult (FOB) test kit (intervention group) or to a control group.

Aims: We have compared the mortality in the intervention group compared with the control group.

Methods: The 152 850 randomised individuals were followed up through local health records and central flagging (Office for National Statistics) over a median follow up period of 11 years.

Results: At a median follow up of 11 years there was a 13% reduction in colorectal cancer mortality (95% confidence interval 3-22%) in the intervention group despite an uptake at first invitation of only approximately 50%. The mortality reduction for those accepting screening was 27%. The reduction in mortality was independent of sex and site of tumour. There was no significant difference in mortality from causes other than colorectal cancer between the intervention and control groups.

Conclusions: Although the reduction in colorectal cancer mortality was sustained, further follow up of this population is required to determine whether a significant reduction in the incidence of colorectal cancer will be achieved.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative incidence of colorectal cancer (CRC) in the control and screened groups.
Figure 2
Figure 2
Cumulative mortality from verified colorectal cancer (CRC) in the control and screened groups.
Figure 3
Figure 3
Nelson-Aalen estimates of cumulative mortality from colorectal cancer (CRC) in the control and screened groups.
See this image and copyright information in PMC

References

    1. Selby JV. Screening sigmoidoscopy for colorectal cancer. Lancet 1993;341:728–9. - PubMed
    1. Saito J, Soma Y, Koeda J. Reduction in risk of mortality from colorectal cancer by fecal occult blood screening with immunochemical hemagglutination test. A case-control study. Int J Cancer 1995;61:465–9. - PubMed
    1. Wahrendorf J, Robra BP, Wiebelt H. Effectiveness of colorectal cancer screening: results from a population-based case-control evaluation in Saarland, Germany. Eur J Cancer Prev 1993;2:221–7. - PubMed
    1. Lazovich DA, Weiss NS, Stevens NG. A case-control study to evaluate efficacy of screening faecal occult blood. J Med Screen 1995;2:84–9. - PubMed
    1. Zappa M, Castiglione G, Grazzini G. Effect of faecal occult blood testing on colorectal cancer mortality: results of a population-based case-control study in the district of Florence, Italy. Int J Cancer 1997;73:208–10. - PubMed

Publication types